NMTC · XBRL financial data

NeuroOne Medical Technologies financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (NMTC's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Revenue	—	178	171	1,952	3,453	9,098
Cost of revenue	—	276	242	1,496	2,373	3,956
Gross profit	—	(98)	(71)	457	1,080	5,141
Research and development	2,076	3,925	4,929	6,941	5,065	4,983
Selling, general and administrative	—	6,260	6,979	6,926	7,902	7,385
General and administrative	4,753	6,260	—	—	6,498	5,848
Total operating expenses	6,829	10,185	11,909	13,867	12,967	12,368
Operating income (loss)	(4,902)	(10,218)	(10,031)	(11,955)	(11,887)	(4,226)
Interest expense	—	3	—	—	—	—
Other income (expense)	—	—	31	96	125	—
Income tax expense (benefit)	—	(271)	—	—	—	—
Net income (loss)	(13,640)	(9,948)	(10,000)	(11,859)	(12,318)	(3,605)
Earnings per share, basic USD per share	—	(0.93)	(0.63)	(0.65)	(0.46)	(0.09)
Earnings per share, diluted USD per share	—	(0.93)	(0.63)	(0.65)	(0.46)	(0.09)
Weighted average shares, basic thousands of shares	—	10,697	15,999	18,121	26,762	40,153
Weighted average shares, diluted thousands of shares	—	10,697	15,999	18,121	26,762	40,153

Fiscal years (NMTC's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Cash and cash equivalents	4,036	6,901	8,160	5,322	1,460	6,570
Short-term investments	—	—	2,981	—	—	—
Accounts receivable	—	48	33	—	177	1,265
Inventory	—	98	705	1,727	2,635	2,227
Prepaid and other current assets	—	—	—	264	216	—
Total current assets	4,155	7,292	12,176	7,313	4,631	10,226
Property and equipment, net	166	223	354	526	417	259
Right-of-use asset	282	289	181	169	255	255
Total assets	4,760	7,938	12,823	8,097	5,370	10,786
Accounts payable	763	529	928	685	1,029	1,010
Accrued liabilities	513	644	716	1,108	1,184	1,293
Total current liabilities	2,356	1,182	3,099	1,793	2,213	2,303
Lease liability, non-current	254	203	120	55	194	143
Total liabilities	2,694	1,385	3,218	1,848	4,548	3,713
Accumulated deficit	(30,879)	(40,827)	(50,827)	(62,686)	(75,004)	(78,610)
Total stockholders' equity	2,066	6,554	9,604	6,249	822	7,073
Total liabilities and equity	4,760	7,938	12,823	8,097	5,370	10,786
Common shares outstanding (cover page) thousands of shares	22,993	16,188	16,238	23,963	30,842	50,413

Fiscal years (NMTC's year ends in late September)

In thousands of dollars	FY 2020Sep 30, 2020	FY 2021Sep 30, 2021	FY 2022Sep 30, 2022	FY 2023Sep 30, 2023	FY 2024Sep 30, 2024	FY 2025Sep 30, 2025
Net income (loss)	(13,640)	(9,948)	(10,000)	(11,859)	(12,318)	(3,605)
Stock-based compensation	—	—	947	1,105	1,344	1,265
Depreciation and amortization	48	81	119	199	—	—
Net cash from operating activities	(3,425)	(8,603)	(7,520)	(12,887)	(11,012)	(2,837)
Purchases of property and equipment	122	67	275	384	120	82
Net cash from investing activities	(122)	(67)	(3,245)	2,650	(120)	(82)
Proceeds from issuing common stock	—	—	—	2,553	5,034	—
Net cash from financing activities	7,323	11,535	12,023	7,399	7,270	8,029
Net change in cash	3,776	2,865	—	—	—	—

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
RenovoRx	9,479	909	(2,867)*	45.1M	3.3 quarters	Q2 FY26 10-QJun 30, 2026
Nephros	4,697	6,017	681*	10.9M	—	Q2 FY26 10-QJun 30, 2026
electroCore	8,501	9,450	(3,518)*	9.0M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
DarioHealth	6,634	not reported	(6,083)*	9.8M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Positron	357	112	(1,050)*	32.8M	0.3 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.